SGO Annual Meeting on Women's Cancer
Highlights from the 48th Annual Meeting of the Society of Gynecologic Oncology, featuring the latest research and insights from those who treat and care for women with gynecologic cancer.
Lynparza Improves Progression-Free Survival in BRCA+ Ovarian Cancer
Patients with BRCA-mutant ovarian cancer saw an improved progression-free survival with Lynparza, according to a recent study.
Improving Survival in BRCA-Proficient Ovarian Cancer
Improved overall survival (OS) was achieved in patients with BRCA-proficient ovarian cancer who were treated with a carboplatin desensitization regimen. 
Jubilee Brown on Genetic Counseling for Patients With Breast and Ovarian Cancer
BY JUBILEE BROWN, M.D.
Jubilee Brown, M.D., obstetrician-gynecologist, Levine Cancer Institute, Carolinas HealthCare System, discusses genetic counseling for patients with breast and ovarian cancer.
 
PARP Inhibitors Are Changing the Treatment Landscape for Ovarian Cancer
BY BRIELLE URCIUOLI
PARP inhibitors like niraparib are bringing big change to the treatment of ovarian cancer, says Kathleen N. Moore, M.D.
Kathleen N. Moore Discusses New PARP Inhibitors for Ovarian Cancer
BY KATHLEEN N. MOORE M.D.
Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.
Niraparib Improves Progression-Free Survival in Ovarian Cancer, Regardless of BRCA Status
The PARP inhibitor niraparib proved to be effective in improving progression-free survival in recurrent ovarian cancer, according to a recent study.
Declining Concern about HPV Vaccine and Sexual Activity
Concern about vaccine safety and perceived lack of necessity remain the main reasons parents give for not having their teenage daughter vaccinated against HPV.
Genetic Counseling and Ovarian Cancer: 4 Questions With an Expert
BY KATIE KOSKO
Jubilee Brown, M.D., answers some common questions about genetic counseling in patients with ovarian cancer.
Ursula Matulonis Explains the Use of PARP Inhibitors for Ovarian Cancer
BY URSULA MATULONIS, M.D.
Ursula Matulonis, M.D., professor of Medicine, Harvard Medical School, Medical Director of Gynecologic Oncology, Dana-Farber Cancer Institute, explains the benefits of PARP inhibitors for patients with ovarian cancer.
Special Feature
Share Your Art
ONS Awards 2017
 
Cure Connections
x